drugset / Trial / NCT00696891
Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults
RandomizedParallel-groupSingle-blindPrevention
Summary
This study is conducted to compare the immunogenicity, reactogenicity and safety of Engerix™-B and HBV-MPL vaccine against hepatitis B infection in an elderly population
Timeline
- Start
- 1997-06
- Primary completion
- 1999-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Engerix-B | Vaccine | — | Intramuscular |
| Subject | HBV-MPL vaccine | Vaccine | — | Intramuscular |